The carphedon research journal

The documented core is solid. Voronina’s 2023 review in the Neurochemical Journal states it directly: phenylpiracetam “was developed at the Institute of Biomedical Problems as a new generation psychostimulant that can increase the mental and physical performance of astronauts at various stages of space flights.” The IBMP was the Soviet space-medicine institute — the organisation whose job was keeping crews functional in orbit. Veinberg and colleagues at the Latvian Institute of Organic Synthesis corroborate from the chemistry side: the molecule “was originally designed as a nootropic drug for the sustenance and improvement of the physical condition and cognition abilities of Soviet space crews.” The paper trail itself reaches back to a 1980 synthesis paper from Zagorevskii’s group and the first pharmacological description in 1983, under the plain descriptive name 4-phenylpiracetam.

Then there is the story everyone quotes. Pilot-cosmonaut Aleksandr Serebrov is said to have described phenylpiracetam in the Soyuz/Mir onboard medical kit during his 197-day expedition, calling it “the equalizer of the whole organism”. It is a wonderful line. It is also — as of our 2026-08-15 verification pass — traceable to exactly one source: a Russian pharma-marketing article archived in 2017, which Wikipedia cites. No Roscosmos document, no IBMP publication, no news archive confirms that any cosmonaut carried or took the drug in flight. We print the anecdote as an anecdote, because the distinction between “developed for cosmonauts” (documented) and “taken by cosmonauts” (undocumented) is precisely the discipline this site exists to demonstrate.

One more boundary worth drawing: the Chernobyl story. Phenylpiracetam is sometimes said to have been given to liquidators. We found no source for that claim anywhere. The closest documented link is a 2016 animal study — phenotropil with palonosetron against acute radiation syndrome in rats and dogs — framed as preserving work capacity in future radiation-accident responders. A real paper about a real programme; not a record of human use at Chernobyl.

Start with the strongest design, because there is exactly one. Grebeniuk, Zhukova and Alifirova randomised 90 adults with symptomatic locally-induced epilepsy to phenotropil (100 or 200 mg) or placebo on top of standard antiepileptics. Seizure frequency and cognition improved in patients without epileptiform EEG abnormalities — and the same abstract reports that the drug did not decrease the negative effects of standard antiepileptic therapy in 40% of patients. Positive and null in one paragraph: that is what a mixed result looks like, and it is the best-controlled human evidence this molecule has.

Around that single trial sits a large open literature. The TRIUMPH programme followed 1,170 chronic-brain-ischemia patients without a control group and reported asthenia severity falling by more than twofold over three months. A 400-patient stroke-rehabilitation comparison reported significantly better functional recovery — without randomisation or blinding stated. Open epilepsy, encephalopathy and dental-premedication reports fill out the corpus. In 2025 the first meta-analysis pooled eleven asthenia studies (549 patients): the MFI-20 score fell by a mean of 16.3 points, with side effects in 5.5% described as transient. Every pooled study is Russian, single-country, and mostly small — and the abstract reports no placebo-controlled pooled estimate.

Context disciplines interpretation. For the parent compound piracetam, the Cochrane review of dementia and cognitive impairment concluded the evidence does not support use — global impression moved, specific measures did not. No Cochrane review of phenylpiracetam exists. No trial originates outside Russia. No trial in healthy volunteers exists at all. And one open study carries the signal nobody markets: the anxiolytic effect of phenotropil decreased after four to eight weeks of continued treatment. The ledger is what it is — promising open signals, one mixed RCT, and a tolerance question that remains open.

The Catlin group’s 2023 review states it verbatim: “The first nootropic prohibited in sport was fonturacetam (4-phenylpiracetam, carphedon) in 1998.” One year later a Korean analytical group published a GC-NPD urine method for carphedon — limit of detection 0.01 µg/mL — written explicitly for stimulant doping analysis. The molecule had gone from cosmonaut programme to controlled substance in fifteen years, and it remains the only racetam on the WADA Prohibited List: S6.A, non-specified stimulants, prohibited in-competition, on the same tier as amphetamine, cocaine and modafinil.

The documented cases are two. Danilo Hondo, the German sprinter, tested positive for carphedon at the 2005 Vuelta a Murcia; his sanction see-sawed from two years to one, back to two at the Court of Arbitration for Sport, before a Swiss civil court ended it early. Olga Pyleva’s case was louder: positive after the 15 km individual at Torino 2006, expelled from the Games, silver medal stripped — the first doping case of those Olympics. The Russian Anti-Doping Committee’s head said an over-the-counter medication for an ankle injury contained the drug; the IBU banned her for two years regardless. Prevalence data from the WADA-accredited Rome laboratory show carphedon among the stimulants found across roughly 100,000 samples from 2000 to 2009.

And the case that is NOT a carphedon case: Olga Vilukhina. The IOC’s Oswald Commission sanctioned her over Sochi 2014 without naming a substance in its public documents, and in 2020 the Court of Arbitration for Sport overturned her individual-race disqualification and restored her sprint silver. Whether carphedon was analytically involved could not be confirmed from any primary source. Sites that list her under carphedon doping cases are repeating an unattributed claim; this one does not.